Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
John J ChenEoin P FlanaganM Tariq BhattiJiraporn JitprapaikulsanDivyanshu DubeyAlfonso Sebastian S Lopez ChiribogaJames P FryerBrian G WeinshenkerAndrew McKeonJan-Mendelt TillemaVanda A LennonClaudia F LucchinettiAmy KunchokCollin M McClellandMichael S LeeJeffrey L BennettVictoria S PelakGregory Van StavernOre-Ofe O AdesinaEric R EggenbergerMarie D AciernoDean M WingerchukByron L LamHeather MossShannon BeresAubrey L GilbertVeeral ShahGrayson ArmstrongGena HeidaryDean M CestariHadas Stiebel-KalishSean J PittockPublished in: Neurology (2020)
This large retrospective multicenter study of patients with MOGAD suggests that maintenance immunotherapy reduces recurrent CNS demyelinating attacks, with the lowest ARR being associated with maintenance IVIG therapy. Traditional MS disease-modifying agents appear to be ineffective. Prospective randomized controlled studies are required to validate these conclusions.